Cardiovascular Drug Developer Braveheart, Backed by A16z and Led by Biogen's CEO, Files for Nasdaq IPO

Stock News07-15 21:45

Clinical-stage biopharmaceutical firm Braveheart Bio Inc., which has the backing of venture capital firm Andreessen Horowitz (a16z), filed for an initial public offering on the Nasdaq exchange on Wednesday.

The company, which focuses on developing treatments for cardiovascular diseases, aims to raise an undisclosed amount of capital through the sale of its shares on the Nasdaq Global Market.

Its leading drug candidate is BHB‑1893, currently in development for the treatment of hypertrophic cardiomyopathy.

To date, the company has secured $185 million in funding from investors, including the a16z Bio + Health fund and Patient Square Capital.

Christopher Viehbacher, the Chief Executive Officer of Biogen Inc. (NASDAQ: BIIB), serves as the Chairman of Braveheart's board.

For the first three months of 2026, Braveheart reported a net loss of $14.3 million and generated revenue of approximately $11 million.

This compares to a net loss of $99,000 for the same period in the prior year.

The joint book-running managers for the offering are Goldman Sachs, Jefferies, TD Cowen, Stifel, and Cantor.

Braveheart will trade on the Nasdaq under the ticker symbol "BRVE".

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1109016136?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-15 21:45","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1109016136","market":"fut","top_or_hot":-1,"title":"Cardiovascular Drug Developer Braveheart, Backed by A16z and Led by Biogen's CEO, Files for Nasdaq IPO","media":"Stock News","content":"<p>Clinical-stage biopharmaceutical firm <b>Braveheart Bio Inc.</b>, which has the backing of venture capital firm Andreessen Horowitz (a16z), filed for an initial public offering on the Nasdaq exchange on Wednesday.<br><br>The company, which focuses on developing treatments for cardiovascular diseases, aims to raise an undisclosed amount of capital through the sale of its shares on the Nasdaq Global Market.<br><br>Its leading drug candidate is BHB‑1893, currently in development for the treatment of hypertrophic cardiomyopathy.<br><br>To date, the company has secured $185 million in funding from investors, including the a16z Bio + Health fund and Patient Square Capital.<br><br>Christopher Viehbacher, the Chief Executive Officer of <b>Biogen Inc. (NASDAQ: BIIB)</b>, serves as the Chairman of Braveheart's board.<br><br>For the first three months of 2026, Braveheart reported a net loss of $14.3 million and generated revenue of approximately $11 million.<br><br>This compares to a net loss of $99,000 for the same period in the prior year.<br><br>The joint book-running managers for the offering are Goldman Sachs, Jefferies, TD Cowen, Stifel, and Cantor.<br><br>Braveheart will trade on the Nasdaq under the ticker symbol \"BRVE\".<br><br></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Cardiovascular Drug Developer Braveheart, Backed by A16z and Led by Biogen's CEO, Files for Nasdaq IPO</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCardiovascular Drug Developer Braveheart, Backed by A16z and Led by Biogen's CEO, Files for Nasdaq IPO\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-07-15 21:45</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Clinical-stage biopharmaceutical firm <b>Braveheart Bio Inc.</b>, which has the backing of venture capital firm Andreessen Horowitz (a16z), filed for an initial public offering on the Nasdaq exchange on Wednesday.<br><br>The company, which focuses on developing treatments for cardiovascular diseases, aims to raise an undisclosed amount of capital through the sale of its shares on the Nasdaq Global Market.<br><br>Its leading drug candidate is BHB‑1893, currently in development for the treatment of hypertrophic cardiomyopathy.<br><br>To date, the company has secured $185 million in funding from investors, including the a16z Bio + Health fund and Patient Square Capital.<br><br>Christopher Viehbacher, the Chief Executive Officer of <b>Biogen Inc. (NASDAQ: BIIB)</b>, serves as the Chairman of Braveheart's board.<br><br>For the first three months of 2026, Braveheart reported a net loss of $14.3 million and generated revenue of approximately $11 million.<br><br>This compares to a net loss of $99,000 for the same period in the prior year.<br><br>The joint book-running managers for the offering are Goldman Sachs, Jefferies, TD Cowen, Stifel, and Cantor.<br><br>Braveheart will trade on the Nasdaq under the ticker symbol \"BRVE\".<br><br></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4588","symbol_name":"碎股","start_time":0,"source_url":"","article_id":"1109016136","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1109016136","pubTimestamp":1784123139,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Clinical-stage biopharmaceutical firm Braveheart Bio Inc., which has the backing of venture capital firm Andreessen Horowitz (a16z), filed for an initial public offering on the Nasdaq exchange on...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4588":"碎股","IE00B894F039.SGD":"Legg Mason ClearBridge - US Aggressive Growth A Acc SGD-H","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","BK4585":"ETF&股票定投概念","IE00B19Z9P08.USD":"LEGG MASON CLEARBRIDGE US AGGRESSIVE GROWTH \"A\" (USD) INC","BK4532":"文艺复兴科技持仓","BK4139":"生物科技","LU0234570918.USD":"高盛全球核心股票组合Acc Close","BK4533":"AQR资本管理(全球第二大对冲基金)","BIIB":"渤健公司","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","BMED":"iShares Health Innovation Active ETF","IE00B19Z9Z06.USD":"Legg Mason ClearBridge - US Aggressive Growth A Acc USD","PBE":"INVESCO BIOTECHNOLOGY & GENOME ETF"},"translate_title":"由A16z支持、百健首席执行官领衔的心血管药物开发商Braveheart申请纳斯达克IPO","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PBE":1,"BRVE":1,"BMED":1,"BIIB":1},"content_text":"Clinical-stage biopharmaceutical firm Braveheart Bio Inc., which has the backing of venture capital firm Andreessen Horowitz (a16z), filed for an initial public offering on the Nasdaq exchange on Wednesday.The company, which focuses on developing treatments for cardiovascular diseases, aims to raise an undisclosed amount of capital through the sale of its shares on the Nasdaq Global Market.Its leading drug candidate is BHB‑1893, currently in development for the treatment of hypertrophic cardiomyopathy.To date, the company has secured $185 million in funding from investors, including the a16z Bio + Health fund and Patient Square Capital.Christopher Viehbacher, the Chief Executive Officer of Biogen Inc. (NASDAQ: BIIB), serves as the Chairman of Braveheart's board.For the first three months of 2026, Braveheart reported a net loss of $14.3 million and generated revenue of approximately $11 million.This compares to a net loss of $99,000 for the same period in the prior year.The joint book-running managers for the offering are Goldman Sachs, Jefferies, TD Cowen, Stifel, and Cantor.Braveheart will trade on the Nasdaq under the ticker symbol \"BRVE\".","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.46.0","shortVersion":"4.46.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1109016136","isCrawlerRequest":true}